Clinical trials: sponsored by Vanda Pharmaceuticals
Healthy Volunteers
Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
The purpose of this research study is to evaluate whether administration of a CYP1A2 inhibitor affects the single-dose pharmacokinetics of tasimelteon and its metabolites.
- Trial name
- NCT01540500
- Testing
- Tasimelteon, Fluvoxamine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients
This study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen.
- Trial name
- NCT01348100
- Testing
- Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Excessive Somnolence
VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
The purpose of this study is to determine the safety and efficacy of VSF-173 compared to placebo in treatment of induced excessive sleepiness.
- Trial name
- NCT00467441
- Testing
- VSF-173
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals